search
Back to results

Ascorbic Acid and Thiamine Effect in Septic Shock (ATESS)

Primary Purpose

Septic Shock, Sepsis

Status
Completed
Phase
Phase 2
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Combination therapy of vitamin C and thiamine
Normal saline solution
Sponsored by
Tae Gun Shin
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Septic Shock focused on measuring Septic shock, Sepsis, Vitamin C, Thiamine

Eligibility Criteria

19 Years - 89 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adult patients (> 18 years)
  2. Septic shock: sepsis with persisting hypotension requiring vasopressors to maintain a mean arterial pressure ≥65 mm Hg and a serum lactate level >2 mmol/L despite adequate volume resuscitation. Sepsis is defined as clinically suspected or confirmed infection with acute organ failure identified as an acute change in total SOFA score with 2 points or more.

Exclusion Criteria:

  1. Transferred patients from other hospitals after application of vasopressors or mechanical ventilation
  2. Patients who signed a "Do not attempt resuscitation" order or who had set limitations on invasive care
  3. Patients who have a terminal, unresponsive illness and survival discharge is not expected (metastatic terminal cancer, etc.)
  4. Patients who experienced cardiac arrest before enrollment or when death is anticipated within 24 hours despite maximal treatment
  5. Patients who take more than 1g of Vitamin C per day before enrollment or who take supplemental thiamine
  6. Pregnant woman
  7. Known Glucose-6-phosphate dehydrogenase deficiency
  8. Patients with a history of hypersensitivity to vitamin C or thiamine
  9. Known Mediterranean anemia
  10. Known hyperoxaluria
  11. Known cystinuria
  12. Acute gout attack
  13. Known oxalate renal stone
  14. Patients who meet the inclusion criteria 24 hours after emergency department arrival or when enrollment is delayed more than 24 hours after diagnosis of septic shock
  15. Inability or refusal of a subject or legal surrogate to give informed consent

Sites / Locations

  • Department of Emergency Medicine, Seoul National University Bundang Hospital,
  • Department of Emergency Medicine, Borame Medical Center, Seoul National University, College of Medicine
  • Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine,
  • Department of Emergency Medicine, Seoul National University College of Medicine,
  • Department of Emergency Medicine, University of Ulsan College of Medicine, Asan Medical Center,
  • Department of Emergency Medicine, Yonsei University College of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Treatment

Control

Arm Description

Combination therapy of vitamin C and thiamine for 2 days.

Normal Saline Solution

Outcomes

Primary Outcome Measures

Delta Sequential Organ Failure Assessment (SOFA) score
72-hour change in SOFA score, which reflected recovery from organ failure (delta SOFA = SOFA at enrollment - SOFA after 72 hours)

Secondary Outcome Measures

28-day mortality
The number of participants who did not survive until Day 28 will be compared between the treatment and the control group
7-day mortality (early death)
The number of participants who did not survive until Day 7 will be compared between the treatment and the control group
90-day mortality
The number of participants who did not survive until Day 90 will be compared between the treatment and the control group
Time to death
Days until death
In-hospital death
The number of participants who did not survive at hospital discharge will be compared between the treatment and the control group
Intensive care unit death (ICU) death
The number of participants who did not survive at ICU discharge from the first index ICU admission will be compared between the treatment and the control group
Time to Shock reversal
Days from enrollment to shock reversal until Day 14. Shock reversal is defined as discontinuation of all vasopressors and mean arterial pressure is maintained at 60 mmHg or more for more than 24 hours.
Vasopressor free days
Days not receiving any vasopressor
Ventilator free days
Days not receiving mechanical ventilation
Ventilator duration
Days receiving mechanical ventilation during hospital stay
Renal replacement therapy (RRT) free days
Days not receiving Renal replacement therapy
New use of renal replacement therapy (RRT)
The number of participants who receive RRT during hospital stay will be compared between the treatment and the control group
New onset or aggravation of acute kidney injury (AKI)
The number of participants who suffer from new onset or aggravation of AKI will be compared between the treatment and the control group
Length of ICU stay
Number of days in the ICU during hospital admission
ICU free day
Days not being in the ICU
Length of hospital stay
Number of days in the hospital during hospital admission

Full Information

First Posted
October 30, 2018
Last Updated
October 27, 2020
Sponsor
Tae Gun Shin
Collaborators
National Research Foundation of Korea
search

1. Study Identification

Unique Protocol Identification Number
NCT03756220
Brief Title
Ascorbic Acid and Thiamine Effect in Septic Shock
Acronym
ATESS
Official Title
Combination Therapy of Vitamin C and Thiamine for Septic Shock: Multi-center, Double-blinded, Randomized, Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
December 1, 2018 (Actual)
Primary Completion Date
January 13, 2020 (Actual)
Study Completion Date
April 14, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Tae Gun Shin
Collaborators
National Research Foundation of Korea

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this study is to evaluate the efficacy of early metabolic resuscitation with combination therapy using vitamin C and thiamine in improving organ function and survival in patients with septic shock.
Detailed Description
Sepsis is a complex disease involving life-threatening organ dysfunction caused by a dysregulated host response to infection and is still associated with unacceptably high mortality. Sepsis management should be undertaken as a medical emergency and focused on timely intervention, including early identification and treatment of infection through appropriate antimicrobial therapy and source control when applicable as well as reversing hemodynamic instability through fluid resuscitation and vasopressor use if necessary. Despite these supportive therapies, morbidity and mortality have remained high, suggesting the need for adjuvant therapies for inflammatory and oxidative stress in patients with sepsis; however, no agents have been proven to definitely improve survival. Vitamin C plays a role in mediating inflammation through antioxidant activities and is also important as a cofactor/co-substrate for the synthesis of endogenous adrenaline, cortisol, and vasopressin. Recently, several clinical trials have reported the positive effects of vitamin C on outcomes in sepsis or septic shock. During sepsis, vitamin C prevents neutrophil-induced lipid oxidation and protects against the loss of the endothelial barrier. Early intravenous supplementation is therefore needed to limit loss of microcirculation and oxidation of lipids. Thiamine is also a key cofactor for glucose metabolism, the generation of ATP (adenosine triphosphate), and the production of NADPH. Considering acute consumption in the hypermetabolic state, thiamine supplementation might be a reasonable therapeutic adjunct for patients with sepsis and was added to reduce the risk of renal oxalate crystallization. These findings led to a recent before-and-after study showing that treatment of sepsis with a combination of vitamin C, hydrocortisone, and thiamine prevented organ dysfunction and reduced the mortality rate. The aim of this study is to evaluate the efficacy of early metabolic resuscitation with combination therapy using vitamin C and thiamine in improving organ function and survival in patients with septic shock.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock, Sepsis
Keywords
Septic shock, Sepsis, Vitamin C, Thiamine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Multi-center, Double-blinded, Randomized, Controlled Study
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
116 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Description
Combination therapy of vitamin C and thiamine for 2 days.
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
Normal Saline Solution
Intervention Type
Drug
Intervention Name(s)
Combination therapy of vitamin C and thiamine
Other Intervention Name(s)
Ascorbic Acid Injection, Thiamine Injection
Intervention Description
Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days
Intervention Type
Drug
Intervention Name(s)
Normal saline solution
Other Intervention Name(s)
0.9% NaCl
Intervention Description
Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days
Primary Outcome Measure Information:
Title
Delta Sequential Organ Failure Assessment (SOFA) score
Description
72-hour change in SOFA score, which reflected recovery from organ failure (delta SOFA = SOFA at enrollment - SOFA after 72 hours)
Time Frame
Enrollment to 72 hours
Secondary Outcome Measure Information:
Title
28-day mortality
Description
The number of participants who did not survive until Day 28 will be compared between the treatment and the control group
Time Frame
Day 28
Title
7-day mortality (early death)
Description
The number of participants who did not survive until Day 7 will be compared between the treatment and the control group
Time Frame
Day 7
Title
90-day mortality
Description
The number of participants who did not survive until Day 90 will be compared between the treatment and the control group
Time Frame
Day 90
Title
Time to death
Description
Days until death
Time Frame
Enrollment to Day 28
Title
In-hospital death
Description
The number of participants who did not survive at hospital discharge will be compared between the treatment and the control group
Time Frame
Up to 12 weeks
Title
Intensive care unit death (ICU) death
Description
The number of participants who did not survive at ICU discharge from the first index ICU admission will be compared between the treatment and the control group
Time Frame
Up to 12 weeks
Title
Time to Shock reversal
Description
Days from enrollment to shock reversal until Day 14. Shock reversal is defined as discontinuation of all vasopressors and mean arterial pressure is maintained at 60 mmHg or more for more than 24 hours.
Time Frame
Enrollment to Day 14
Title
Vasopressor free days
Description
Days not receiving any vasopressor
Time Frame
Enrollment to Day 14
Title
Ventilator free days
Description
Days not receiving mechanical ventilation
Time Frame
Enrollment to Day 14
Title
Ventilator duration
Description
Days receiving mechanical ventilation during hospital stay
Time Frame
Up to 12 weeks
Title
Renal replacement therapy (RRT) free days
Description
Days not receiving Renal replacement therapy
Time Frame
Enrollment to Day 14
Title
New use of renal replacement therapy (RRT)
Description
The number of participants who receive RRT during hospital stay will be compared between the treatment and the control group
Time Frame
Up to 12 weeks
Title
New onset or aggravation of acute kidney injury (AKI)
Description
The number of participants who suffer from new onset or aggravation of AKI will be compared between the treatment and the control group
Time Frame
Enrollment to Day 14
Title
Length of ICU stay
Description
Number of days in the ICU during hospital admission
Time Frame
Up to 12 weeks
Title
ICU free day
Description
Days not being in the ICU
Time Frame
Enrollment to Day 14
Title
Length of hospital stay
Description
Number of days in the hospital during hospital admission
Time Frame
Up to 12 weeks
Other Pre-specified Outcome Measures:
Title
CRP (C-reactive protein) change during initial 72 hours
Description
72-hour change in CRP (%)
Time Frame
Enrollment to 72 hours
Title
Procalcitonin change during initial 72 hours
Description
72-hour change in procalcitonin (%)
Time Frame
Enrollment to 72 hours
Title
Dose of vasopressor at 24-hour
Description
Norepinephrine equivalent dose at 24 hours from enrollment
Time Frame
Enrollment to 24 hours
Title
Dose of vasopressor at 48-hour
Description
Norepinephrine equivalent dose at 48 hours from enrollment
Time Frame
Enrollment to 48 hours
Title
Dose of vasopressor at 72-hour
Description
Norepinephrine equivalent dose at 72 hours from enrollment
Time Frame
Enrollment to 72 hours
Title
Maximum dose of vasopressor during initial 72 hours
Description
Maximum norepinephrine equivalent dose during initial 72 hours
Time Frame
Enrollment to 72 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
89 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients (> 18 years) Septic shock: sepsis with persisting hypotension requiring vasopressors to maintain a mean arterial pressure ≥65 mm Hg and a serum lactate level >2 mmol/L despite adequate volume resuscitation. Sepsis is defined as clinically suspected or confirmed infection with acute organ failure identified as an acute change in total SOFA score with 2 points or more. Exclusion Criteria: Transferred patients from other hospitals after application of vasopressors or mechanical ventilation Patients who signed a "Do not attempt resuscitation" order or who had set limitations on invasive care Patients who have a terminal, unresponsive illness and survival discharge is not expected (metastatic terminal cancer, etc.) Patients who experienced cardiac arrest before enrollment or when death is anticipated within 24 hours despite maximal treatment Patients who take more than 1g of Vitamin C per day before enrollment or who take supplemental thiamine Pregnant woman Known Glucose-6-phosphate dehydrogenase deficiency Patients with a history of hypersensitivity to vitamin C or thiamine Known Mediterranean anemia Known hyperoxaluria Known cystinuria Acute gout attack Known oxalate renal stone Patients who meet the inclusion criteria 24 hours after emergency department arrival or when enrollment is delayed more than 24 hours after diagnosis of septic shock Inability or refusal of a subject or legal surrogate to give informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tae Gun Shin, MD, PhD
Organizational Affiliation
Samsung Medical Center, Sungkyunkwan University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Emergency Medicine, Seoul National University Bundang Hospital,
City
Seongnam
State/Province
Gyeonggi-do
Country
Korea, Republic of
Facility Name
Department of Emergency Medicine, Borame Medical Center, Seoul National University, College of Medicine
City
Seoul
Country
Korea, Republic of
Facility Name
Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine,
City
Seoul
Country
Korea, Republic of
Facility Name
Department of Emergency Medicine, Seoul National University College of Medicine,
City
Seoul
Country
Korea, Republic of
Facility Name
Department of Emergency Medicine, University of Ulsan College of Medicine, Asan Medical Center,
City
Seoul
Country
Korea, Republic of
Facility Name
Department of Emergency Medicine, Yonsei University College of Medicine
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26903338
Citation
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.
Results Reference
background
PubMed Identifier
28098591
Citation
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017 Mar;45(3):486-552. doi: 10.1097/CCM.0000000000002255.
Results Reference
background
PubMed Identifier
28934705
Citation
Teng J, Pourmand A, Mazer-Amirshahi M. Vitamin C: The next step in sepsis management? J Crit Care. 2018 Feb;43:230-234. doi: 10.1016/j.jcrc.2017.09.031. Epub 2017 Sep 18.
Results Reference
background
PubMed Identifier
27940189
Citation
Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. Chest. 2017 Jun;151(6):1229-1238. doi: 10.1016/j.chest.2016.11.036. Epub 2016 Dec 6.
Results Reference
background
PubMed Identifier
25185110
Citation
Oudemans-van Straaten HM, Spoelstra-de Man AM, de Waard MC. Vitamin C revisited. Crit Care. 2014 Aug 6;18(4):460. doi: 10.1186/s13054-014-0460-x.
Results Reference
background
PubMed Identifier
26771781
Citation
Donnino MW, Andersen LW, Chase M, Berg KM, Tidswell M, Giberson T, Wolfe R, Moskowitz A, Smithline H, Ngo L, Cocchi MN; Center for Resuscitation Science Research Group. Randomized, Double-Blind, Placebo-Controlled Trial of Thiamine as a Metabolic Resuscitator in Septic Shock: A Pilot Study. Crit Care Med. 2016 Feb;44(2):360-7. doi: 10.1097/CCM.0000000000001572.
Results Reference
background
PubMed Identifier
27162802
Citation
Zabet MH, Mohammadi M, Ramezani M, Khalili H. Effect of high-dose Ascorbic acid on vasopressor's requirement in septic shock. J Res Pharm Pract. 2016 Apr-Jun;5(2):94-100. doi: 10.4103/2279-042X.179569.
Results Reference
background
PubMed Identifier
24484547
Citation
Fowler AA 3rd, Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C, Farthing CA, Larus TL, Martin E, Brophy DF, Gupta S; Medical Respiratory Intensive Care Unit Nursing; Fisher BJ, Natarajan R. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. J Transl Med. 2014 Jan 31;12:32. doi: 10.1186/1479-5876-12-32.
Results Reference
background
PubMed Identifier
23581713
Citation
May JM, Harrison FE. Role of vitamin C in the function of the vascular endothelium. Antioxid Redox Signal. 2013 Dec 10;19(17):2068-83. doi: 10.1089/ars.2013.5205. Epub 2013 May 29.
Results Reference
background
PubMed Identifier
27501325
Citation
Leite HP, de Lima LF. Metabolic resuscitation in sepsis: a necessary step beyond the hemodynamic? J Thorac Dis. 2016 Jul;8(7):E552-7. doi: 10.21037/jtd.2016.05.37.
Results Reference
background
PubMed Identifier
28231816
Citation
de Grooth HJ, Geenen IL, Girbes AR, Vincent JL, Parienti JJ, Oudemans-van Straaten HM. SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis. Crit Care. 2017 Feb 24;21(1):38. doi: 10.1186/s13054-017-1609-1.
Results Reference
background
PubMed Identifier
34482319
Citation
Park JE, Jo YH, Hwang SY, Kim WY, Ryoo SM, Jang DH, Kim T, Kim YJ, Kim S, Cho H, Lee GT, Chung SP, Choi SH, Shin TG, Suh GJ; Korean Shock Society (KoSS) Investigators. Biomarker Analysis for Combination Therapy of Vitamin C and Thiamine in Septic Shock: A Post-Hoc Study of the ATESS Trial. Shock. 2022 Jan 1;57(1):81-87. doi: 10.1097/SHK.0000000000001850.
Results Reference
derived
PubMed Identifier
31296251
Citation
Hwang SY, Park JE, Jo IJ, Kim S, Chung SP, Kong T, Shin J, Lee HJ, You KM, Jo YH, Kim D, Suh GJ, Kim T, Kim WY, Kim YJ, Ryoo SM, Choi SH, Shin TG; Korean Shock Society (KoSS) Investigators. Combination therapy of vitamin C and thiamine for septic shock in a multicentre, double-blind, randomized, controlled study (ATESS): study protocol for a randomized controlled trial. Trials. 2019 Jul 11;20(1):420. doi: 10.1186/s13063-019-3542-x.
Results Reference
derived

Learn more about this trial

Ascorbic Acid and Thiamine Effect in Septic Shock

We'll reach out to this number within 24 hrs